Literature DB >> 15819166

Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.

Hannah Silberer1, Bruno Küppers, Oliver Mickisch, Wojtek Baniewicz, Maren Drescher, Lydia Traber, Alexander Kempf, Heinrich Schmidt-Gayk.   

Abstract

UNLABELLED: The aim of this prospective study was to compare five different leukocyte proteins in feces of patients with chronic inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and healthy persons who underwent prophylactic colonoscopy.
METHODS: The leukocyte proteins calprotectin, lactoferrin, lysozyme, myeloperoxidase, and PMN-elastase were determined with immunoassays in fecal samples of three consecutive feces (e.g. three days) in 40 healthy persons, 39 patients with chronic IBD (of these 21 with Crohn's disease and 18 with ulcerative colitis), and 40 patients with IBS.
RESULTS: ROC curves calculated for healthy persons and patients with IBD yielded the following areas under the curves (AUCs): PMN-elastase 0.916, calprotectin 0.872, myeloperoxidase 0.750, lysozyme 0.726, and lactoferrin 0.693. The AUCs of PMN-elastase and calprotectin were not significantly different (p = 0.327), whereas PMN-elastase or calprotectin vs. the other proteins were significantly different (p < 0.001). PMN-elastase and calprotectin correlated with the endoscopically classified severity of inflammation. All fecal leukocyte markers in IBS were found in the range of the healthy persons. Data on storage stability of leukocyte proteins in fecal supernatants are given.
CONCLUSION: Fecal PMN-elastase and calprotectin support the differentiation of chronic IBD from IBS and correlate with the severity of inflammation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15819166

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  33 in total

1.  Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis.

Authors:  Tarang Taghvaei; Iradj Maleki; Farshad Nagshvar; Hafez Fakheri; Vahid Hosseini; Seyed Mohammad Valizadeh; Hassan Neishaboori
Journal:  Intern Emerg Med       Date:  2014-11-04       Impact factor: 3.397

Review 2.  Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.

Authors:  Yan Wang; Fengyan Pei; Xingjuan Wang; Zhiyu Sun; Chengjin Hu; Hengli Dou
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections.

Authors:  M M Gaida; F Günther; C Wagner; H Friess; N A Giese; J Schmidt; G M Hänsch; M N Wente
Journal:  Clin Exp Immunol       Date:  2008-09-05       Impact factor: 4.330

4.  Sputum proteomics in inflammatory and suppurative respiratory diseases.

Authors:  Robert D Gray; Gordon MacGregor; Donald Noble; Margaret Imrie; Maria Dewar; A Christopher Boyd; J Alastair Innes; David J Porteous; Andrew P Greening
Journal:  Am J Respir Crit Care Med       Date:  2008-06-19       Impact factor: 21.405

Review 5.  Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update.

Authors:  Cansel Turkay; Benan Kasapoglu
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

Review 6.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

Review 7.  Progressing from Recurring Tissue Injury to Genomic Instability: A New Mechanism of Neutrophil Pathogenesis.

Authors:  Triet M Bui; Ronen Sumagin
Journal:  DNA Cell Biol       Date:  2019-06-12       Impact factor: 3.311

8.  Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes.

Authors:  Andrea Vieira; Chia Bin Fang; Ernani Geraldo Rolim; Wilmar Artur Klug; Flávio Steinwurz; Lucio Giovanni Battista Rossini; Paulo Azevedo Candelária
Journal:  BMC Res Notes       Date:  2009-10-29

Review 9.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 10.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.